Abstract: A means for treating cardiovascular disease, in particular chronic heart failure, especially in terms of a more specific treatment preventing or minimizing pathological hypertrophic signaling while leaving cardiac contractility largely intact. For this purpose the present invention provides a means for treating cardiovascular disease, in particular chronic heart failure, the means specifically inhibiting or causing inhibition of components of the ?1-AR/cAMP pathway generating cAMP resulting from activation of the ?1-adrenoceptor on the cardiomyocyte cell crest.

Abstract: A means for treating cardiovascular disease, in particular chronic heart failure, especially in terms of a more specific treatment preventing or minimizing pathological hypertrophic signaling while leaving cardiac contractility largely intact. For this purpose the present invention provides a means for treating cardiovascular disease, in particular chronic heart failure, the means specifically inhibiting or causing inhibition of components of the ?1-AR/cAMP pathway generating cAMP resulting from activation of the ?1-adrenoceptor on the cardiomyocyte cell crest.

Abstract: The present invention relates to novel ?-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-?-adrenergic receptor antibodies like anti-?-adrenergic receptor antibodies.

Abstract: The present invention relates to novel ?-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-.beta.-adrenergic receptor antibodies like anti-?1-adrenergic receptor antibodies.

Abstract: Described is a chimeric peptide, comprising, in order, (a) a first detectable label (b) a cAMP binding moiety having only one cAMP binding site and (c) a second detectable label least two detectable labels is describe. The chimeric peptide is useful for direct determination of cAMP concentration in vitro and/or in vivo. Also described are nucleic acids encoding the chimeric peptide, methods of making and modifying the chimeric peptide, a method for determining the cAMP concentration, and kits.

Abstract: The present invention relates to novel ?-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-?-adrenergic receptor antibodies like anti-?radrenergic receptor antibodies.

Abstract: The present invention relates to a chimeric peptide, comprising a cAMP binding moiety having only one cAMP binding site and at least two detectable labels, whereby the first of said two detectable labels is located at the carboxy terminus and the second of said two detectable labels is located at the amino terminus of said cAMP binding moiety. Said chimeric peptide of the invention is particularly useful in/for direct determination of cAMP concentrations) in vitro and/or in vivo. Furthermore, nucleic acid molecules encoding said chimeric proteins are described as well as vectors and host cells comprising the same. The present invention also provides methods for producing the chimeric protein of the invention and methods for identification and screening of molecules or compounds which are capable of modifying cAMP binding to the chimeric peptide of the invention or the biological and/or pharmacological function of adenylyl cyclases or phosphodiesterases.